Pipeline
| Programme | Target | Indication | Research | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| BA368 | dual drug, CDKs + Transcription | cancer + Virus | complete | complete | licensed to Psortech | ||
| BA1248 | betulin | melanoma | complete | development was stopped due to low effectivity | |||
| BA2123 | nucleoside | leukemia | complete | 2017 | 2020 | 2022 | TBD |
| BA1521 | NRF2 regulator | psoriasis, MS | complete | complete | complete | 2017 | TBD |
* final clinical testing as antipsoriatic compound in development
